Patrick Lippiello

Summary

Affiliation: Targacept Inc
Country: USA

Publications

  1. ncbi Nicotinic cholinergic antagonists: a novel approach for the treatment of autism
    P M Lippiello
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Med Hypotheses 66:985-90. 2006
  2. ncbi Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties
    Patrick Lippiello
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:19-20. 2006
  3. ncbi TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity
    Patrick M Lippiello
    Targacept, Inc, Winston Salem, North Carolina 27101, USA
    CNS Neurosci Ther 14:266-77. 2008

Collaborators

Detail Information

Publications3

  1. ncbi Nicotinic cholinergic antagonists: a novel approach for the treatment of autism
    P M Lippiello
    Preclinical Research, Targacept, Inc, Winston Salem, NC 27101, USA
    Med Hypotheses 66:985-90. 2006
    ..Clearly there is a need for carefully controlled clinical studies with novel selective NNR antagonists to explore their potential as a new and exciting approach for the treatment of autism...
  2. ncbi Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties
    Patrick Lippiello
    Preclinical Research, Targacept Inc, Winston Salem, NC 27101, USA
    J Mol Neurosci 30:19-20. 2006
    ..Thus, a challenge in nAChR drug design and development has been the reduction of undesirable effects that result from activity at specific nAChRs in the CNS and PNS, including cardiovascular toxicity, emesis, seizures, and hypothermia...
  3. ncbi TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity
    Patrick M Lippiello
    Targacept, Inc, Winston Salem, North Carolina 27101, USA
    CNS Neurosci Ther 14:266-77. 2008
    ....